Home / Pharma News

Pharma News

Alvotech makes deal with Fuji Pharma for biosimilars in Japan

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 19 November 2018 that they had entered into an exclusive partnership for biosimilars in Japan.

AbbVie makes more deals delaying adalimumab biosimilars in US

US-based pharma giant AbbVie has signed yet more deals with biosimilars makers regarding biosimilar versions of its blockbuster arthritis drug Humira (adalimumab).

Amgen collaborates with Orion to market Amgevita in Finland

The Orion Group announced on 24 October 2018 that it will distribute Amgen’s adalimumab biosimilar in Finland.

Momenta to reduce its biosimilars programmes

US-based biotechnology firm Momenta Pharmaceuticals (Momenta) announced on 1 October 2018 that it would be focusing on two key biosimilars and quit the development of five others.

Biosimilar partnerships for Alvotech and Pall Biotech

Partnering to develop biosimilars is still in vogue. The latest companies to join the trend include Alvotech with Changchun High & New Technology Industries Group (CCHN) and Pall Corporation’s Biotech business (Pall Biotech) with Aetos Biologics.

Mundipharma buys Spanish biosimilars maker Cinfa Biotech

UK-based Mundipharma International (Mundipharma) is strengthening its position in biosimilars with the acquisition of Spanish biosimilars maker Cinfa Biotech.

MENA mAb manufacturer AryoGen receives EU GMP approval

Iran-based AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified [1].

Co-development deal for ranibizumab biosimilar Xlucane

German generics giant Stada and Swedish biotech company Xbrane announced on 12 July 2018 that they had entered into a co-development agreement for Xlucane, a proposed biosimilar to Lucentis (ranibizumab).

AbbVie signs another licensing deal for adalimumab biosimilar

US-based pharma giant AbbVie has signed yet another licensing deal for a biosimilar version of its blockbuster arthritis drug Humira (adalimumab).

Mylan and Lupin make deal for etanercept biosimilar

Indian generics manufacturer Lupin Pharmaceuticals (Lupin) and US-based drugmaker Mylan announced on 28 June 2018 that they had made a deal to commercialize an etanercept biosimilar.